Oral Administration of Actitan-F in Paediatric Diarrhoea
NCT ID: NCT05904938
Last Updated: 2024-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
136 participants
INTERVENTIONAL
2023-07-10
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children
NCT01295918
Efficacy of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders
NCT02722993
L Rhamnosus ATCC 53103 & L Reuteri DSM 29063 Compared With L Rhamnosus ATCC 53103 for Preventing AAD in Children
NCT04277156
Randomized Controlled Field Trial of a Probiotics to Assess Its Role in Preventig Diarrhoea
NCT00534170
Bacillus Particles Prevent Children Antibiotics Associated Diarrhea
NCT02993419
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lenodiar Pediatric
Medical Device
Lenodiar Pediatric
Medical Device made of natural substance
Placebo
Placebo
Placebo
Product appearance similar to verum without clinical efficacy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lenodiar Pediatric
Medical Device made of natural substance
Placebo
Product appearance similar to verum without clinical efficacy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of chronic diarrhoea due to the following conditions:
* Functional gastrointestinal disorder fulfilling Rome IV Criteria\*
* or
* Functional gastrointestinal disorder fulfilling modified Rome IV Criteria \*\*
* or
* Post-infectious diarrea with daily painless, recurrent passage of three or more large, unformed stools
* Parents/legal guardians\*\*\* availability to fill on a daily basis the electronic daily diary by a smartphone/tablet.
* Parents/legal guardians have given a written informed consent for participation in the investigation at the time of enrolment or before. The parent/legal guardian should also have agreed to bring the child for the visits scheduled in the protocol and to provide the requested information during the telephonic follow-up visit;
* Parents/legal guardian able to understand the full nature and the purpose of the investigation, including possible risks and side effects, able to cooperate with the Investigator and to comply with the requirements of the entire investigation (ability to attend all the planned investigation visits according to the time limits included) based on Investigator's judgement;
* Willingness not to make diet and lifestyle significant changes during the trial.
* Rome IV criteria of functional diarrhoea (Neonate and Toddlers below 5 years), must include all of the following:
* Daily painless, recurrent passage of four or more large, unformed stools
* Symptoms last more than 4 weeks
* Onset between 6 and 60 months of age
* No failure-to-thrive if caloric intake is adequate
\*\* Modified Rome IV criteria of functional diarrhoea (Neonate and Toddlers below 5 years), must include all of the following:
* Daily painless, recurrent passage of three or more large, unformed stools
* Symptoms last more than 2 weeks (Nelson Pediatric Texbook 21st Edition, Chronic diarrhea)
* Onset between 6 and 60 months of age
* No failure-to-thrive if caloric intake is adequate
* These criteria have been modified in order to align the study to the functional diarrhoea condition in the real life.
* Parent is the child's biological or adoptive parent. Legal guardian is defined as an individual who was authorized under applicable state or local law to consent on behalf of a child to general medical care, when general medical care includes participation in research. A guardian also meant an individual who was authorized to consent on behalf of a child to participate in research.
Exclusion Criteria
* Patients with any of the following chronic gastrointestinal disorders: inflammatory bowel disease, pancreatitis, chronic liver disease, eosinophilic oesophagitis, peptic ulcer disease, celiac disease, pseudo-obstruction, small bowel bacterial overgrowth, or Hirschsprung's disease
* Significant chronic health condition requiring specialty care (e.g., lithiasis, ureteropelvic junction obstruction, sickle cell, cerebral palsy, hepatic, hematopoietic, renal, endocrine, or metabolic diseases) that could potentially impact the child's ability to participate or confound the results of the investigation;
* Gastrointestinal blood loss;
* Recurrent or unexplained fevers;
* Developmental disabilities impairing ability to understand or communicate;
* History of hypersensitivity or allergy to investigational product;
* History of previous abdominal surgeries in the past 3 months;
* Known hypersensitivity to any of the components (active ingredients or excipients) of the investigational product;
* Conditions known to producing immunodeficiency (AIDS, other congenital immunodeficiency syndromes, drugs therapy with steroids, anticancer drugs, etc.);
* Patients who have received any of the following treatments within the 2 weeks before the baseline visit:
* Agents specially developed for achieving adsorbing properties, e.g. kaolin, pectin, bismuth subsalicylate;
* Treatments that modify intestinal secretions, e.g. racecadotril;
* Treatments that modify intestinal motility, e.g. opiates, anti-cholinergic agents;
* Systemic Antibiotics;
* Antiemetic agents.
* Patients who have received probiotics and prebiotics within the 1 week before the baseline visit, unless they have been taken at stable dose (the use of probiotics and prebiotics in dairy food such as yoghurt, cheese, milk prior to the investigation is permitted);
* Parents/legal guardians' refusal or inability to give written informed consent to participate in the investigation;
* Parents/legal guardians who, in the opinion of the Investigator, are unable to fill up the electronic patient diary;
* Patients who have participated in any other clinical trial in the last 3 months prior to the start of the investigation.
* Applicable only for patients with Functional gastrointestinal disorder fulfilling Rome IV Criteria.
1 Year
5 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IQVIA RDS Inc.
INDUSTRY
IQVIA Solutions
UNKNOWN
Aboca Spa Societa' Agricola
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Azienda Ospedaliera Universitaria "Federico II",
Napoli, Italia, Italy
ASST Papa Giovanni XXIII
Bergamo, , Italy
Azienda Ospedaliera Cannizzaro, UOC Pediatria e PS Pediatrico
Catania, , Italy
Policlinico "SS. Annunziata" Clinica Pediatrica Via dei Vestini, Località colle dell'Ara 66100, Chieti
Chieti, , Italy
IRCCS AOU Meyer SOC Gastroenterologia e Nutrizione, Viale Gaetano Pieraccini 24
Florence, , Italy
Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo Presidio San Carlo, Ambulatorio di Gastroenterologia Pediatrica
Milan, , Italy
Azienda Ospedaliera Universitaria- Università degli Studi della Campania "Luigi Vanvitelli", I Clinica Pediatrica
Napoli, , Italy
ARNAS Ospedale Civico e Benfratelli G Cristina e M Ascoli, Pediatria ad Indirizzo Gastroenterologico
Palermo, , Italy
Fondazione IRCCS Policlinico San Matteo, Pediatria
Pavia, , Italy
Ospedale S. Maria della Misericordia
Perugia, , Italy
Ospedale San Jacopo di Pistoia, SOC Pediatria
Pistoia, , Italy
U.O. di Gastroenterologia e Riabilitazione Nutrizionale Ospedale Pediatrico Bambin Gesu Piazza S. Onofrio, 4 00165, Roma
Roma, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Naire Sansotta, Dr
Role: primary
Rita Cozzali, Dr
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ABO-LENP-01/22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.